PubMed
A synthetic fragment of human growth hormone promotes lipid mobilization
Heffernan MA, Thorburn AW, Fam B, et al. Int J Obes Relat Metab Disord. 2001
Compare
AOD-9604 vs Tesamorelin
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
AOD-9604
44 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
155
Recovery
155
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
2
Injection site irritation
1
Self-reported dose per injection
Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
4
0.2–0.4 mg
113
0.4–0.6 mg
37
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 100% said they felt similar to their last entry, 0% more positive, and 0% more negative.
Overall, repeat reporters leaned similar or mixed compared to their previous entry.
Median gap between entries: 54 days · Based on 30 repeat reporters
Tesamorelin
114 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 3% · Mixed 97% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
224
Sleep
1
Recovery
1
Libido
1
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Injection site irritation
113
Water retention
106
Self-reported dose per injection
Median bucket: 1–2 mg · Most common: 1–2 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
9
0.1–0.2 mg
1
0.2–0.4 mg
5
0.4–0.6 mg
5
0.6–1 mg
4
1–2 mg
126
2–3 mg
74
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 46 days · Based on 41 repeat reporters
Sources (11)
Published sources linked on the AOD-9604 and Tesamorelin wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
A synthetic human growth hormone fragment enhances proteoglycan synthesis
Ng FM, Sun J, Sharma L, et al. Osteoarthritis Cartilage. 2010
- Wiki study page →Source
ClinicalTrials.gov
AOD9604 studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Heffernan MA, Thorburn AW, Fam B, et al. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity. 2001
- Wiki study page →Source
PubMed
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Heffernan M, Summers RJ, Thorburn A, et al. Endocrinology. 2001
- Wiki study page →Source
FDA Drug Label
EGRIFTA (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2010
- Wiki study page →Source
PubMed
Growth hormone-releasing peptides: clinical applications
Ghigo E, Arvat E, Camanni F. Endocrine. 2008
- Wiki study page →Source
ClinicalTrials.gov
Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
FDA Drug Label
EGRIFTA SV (tesamorelin) for injection - Prescribing Information
Theratechnologies. FDA Drug Label. 2019
- Wiki study page →Source
PubMed
Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy
Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012
- Wiki study page →Source
PubMed
Tesamorelin
2018